| Outcome Measures: |
Primary: Heart rate: nighttime, daytime and 24-h, heart rate variability will be evaluated with ambulatory blood pressure monitoring (ABPM) for 24 h by oscillometric method Microlife WatchBP O3, Baseline to Week 4|Systolic blood pressure, daytime, night and 24 h, Blood pressure variability will be evaluated with ambulatory blood pressure monitoring (ABPM) for 24 h by oscillometric method Microlife WatchBP O33., Baseline to Week 4|Diastolic blood pressure, daytime, night and 24 h, Blood pressure variability will be evaluated with ambulatory blood pressure monitoring (ABPM) for 24 h by oscillometric method Microlife WatchBP O3, Baseline to Week 4|Blood pressure, Blood pressure will be measured at baseline and week 4 with a digital sphygmomanometer and the entered values reflect the blood pressure., Baseline to Week 4 | Secondary: Categories: dipper o non dipper, Blood pressure variability will be evaluated with ambulatory blood pressure monitoring (ABPM) for 24 hrs by oscillometric method Microlife WatchBP O3, Baseline to Week 4|Fasting glucose levels, The fasting glucose levels will be evaluated at baseline and week 4 with enzymatic/colorimetric techniques and the entered values reflect the fasting glucose level at week 4, Baseline to Week 4|Central and peripheral blood pressure, To determine and compare the effect of administration of Exenatide LAR or Dulaglutide on Central and peripheral blood pressure through HEM will be evaluated at baseline and week 4., Baseline to Week 4|Pulse wave velocity, To determine and compare the effect of administration of Exenatide LAR or Dulaglutide on pulse wave velocity through VP1000-plus with Ankle-Brachial Index will be evaluated at baseline and week 4., Baseline to Week 4|Cardio-ankle Vascular Index (CAVI), To determine and compare the effect of administration of Exenatide LAR or Dulaglutide on arterial stiffness through Cardio-ankle Vascular Index (CAVI) will be evaluated at baseline and week 4., Baseline to Week 4|Glycosylated hemoglobin, Glycosylated hemoglobin will be evaluated at baseline and week 4 by high pressure liquid chromatography (HPLC) and the entered values reflect the glycosylated hemoglobin at week 4, Baseline to Week 4|Body Weight, The body weight will be measured at baseline and week 4 with a bioimpedance balance and the entered values reflect the body weight at week 4, Baseline to Week 4|Body Mass Index, Body Mass Index will be calculated at baseline and week 4 with the Quetelet index formula and the entered values reflect the body mass index at week 4, Baseline to Week 4|Total cholesterol, Total cholesterol levels will be evaluated at baseline and week 4 by enzymatic/colorimetric techniques and the entered values reflect the total cholesterol level at week 4, Baseline to Week 4|Triglycerides levels, Triglycerides levels will be evaluated at baseline and week 4 with enzymatic/colorimetric techniques and the entered values reflect the triglycerides level at week 4, Baseline to Week 4|High density lipoprotein (c-HDL) levels, c-HDL levels will be evaluated at baseline and week 4 with enzymatic/colorimetric techniques and the entered values reflect the c-HDL level at week 4, Baseline to Week 4|Alanine aminotransferase (ALT) levels, ALT levels will be evaluated at baseline and week 4 with enzymatic/colorimetric techniques, Baseline to Week 4|Aspartate aminotransferase (AST) levels, AST levels will be evaluated at baseline and week 4 with enzymatic/colorimetric techniques \[Time Frame: Baseline to Week 4, Baseline to Week 4|Creatinine levels, Creatinine levels will be evaluated at baseline and week 4 with enzymatic/colorimetric techniques, Baseline to Week 4|Uric acid levels, Uric acid levels will be evaluated at baseline and week 4 with enzymatic/colorimetric techniques, Baseline to Week 4|Waist Circumference, Waist circumference will be evaluated at baseline and at week 4 with a flexible tape, Baseline, week 4
|
